Please select the option that best describes you:
Would you consider maintenance immunotherapy after cisplatin-gemcitabine chemotherapy and chemoRT for stage 3 bladder cancer in a patient declining cystectomy or who is a poor surgical candidate?
If so, which checkpoint inhibitor would you use?
Answer from: Medical Oncologist at Academic Institution
Great question and relevant clinical scenario. We need a clinical trial in this setting, the INSPIRE (EA8185, PI: Dr. @Monika Joshi) is an ideal trial to enroll. In the meantime, would not add "consolidation/maintenance" ICI in the absence of data in this particular setting.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
There are no high-level data to guide further therapy in this setting following induction cisplatin-gemcitabine chemotherapy and chemoRT for stage 3 bladder cancer in a patient declining cystectomy or who is a poor surgical candidate. Given that phase III data are unlikely to be available to guide t...